Gedeon Richter Italia Srl

What Gedeon Richter Italia Srl does

Gedeon Richter Italia Srl is the Italian subsidiary of Hungary-based Gedeon Richter Plc, a multinational pharmaceutical group founded in 1901. The Italian entity was established around 2009 and operates from Milan with approximately 80 employees. It commercializes the parent group's portfolio in Italy across three therapeutic pillars: women's health (contraception, fertility, menopause, benign gynecological conditions, endometriosis), neuropsychiatry (anchored by the blockbuster antipsychotic cariprazine, which generates over $1B in annual revenue globally), and biotechnology/biosimilars (rheumatology, osteoporosis, oncology supportive care), plus generic drugs.

The subsidiary runs an enterprise field-sales model targeting gynecologists, psychiatrists, and pharmacists, complemented by a credentialed Academy area for specialist education. Gedeon Richter Italia also drives disease-awareness and educational campaigns (My Body Match, Il Momento Giusto, ENDOVISION, Mannaggia al Sesso) through partnerships with patient associations, hospitals, NGOs, and consumer brands like KIKO Milano. The parent group invests roughly 10% of consolidated revenue in R&D (48.9 billion HUF in 2019), operates 1,200+ R&D personnel across 11 active projects, and runs a vertically integrated biologics manufacturing capability through its Richter Helm Biologics JV with Helm AG.

Revenue is generated through one-time product sales of branded and generic pharmaceuticals under standard Italian reimbursement and pricing channels; specific pricing or revenue figures for the Italian subsidiary are not publicly disclosed. The group-wide model derives over 90% of revenue from exports across more than 100 countries via 29 representative offices and 41 commercial companies on 5 continents.

Name

Gedeon Richter Italia Srl

Legal name

Gedeon Richter Italia S.r.l.

Website

https://gedeonrichter.it

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

Gedeon Richter Italia Srl is the Italian subsidiary of Hungary's Gedeon Richter Plc, commercializing pharmaceuticals in women's health, neuropsychiatry, and biosimilars. It sells through field-based medical representatives targeting gynecologists, psychiatrists, and pharmacists across Italy.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Pharmaceutical manufacturing
• Women's health drugs
• Neuropsychiatry medicines
• Biosimilar production
• Generic pharmaceuticals

Headquarters

HQ city

Milan

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: Sale of innovative pharmaceutical products including original drugs, biologics, and generic medications across therapeutic areas including women's health, neuropsychiatry, and osteoporosis. Products commercialized in Hungary and over 100 other countries.
2. Cariprazine Global Sales: Blockbuster antipsychotic drug generating annual revenue exceeding $1 billion, approved by FDA and EMA, sold in nearly 50 countries.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels11 records

Core offering

Gedeon Richter Italia Srl is the Italian subsidiary of Gedeon Richter Plc, a multinational pharmaceutical company that develops, manufactures, and commercializes innovative medicines in women's health and neuropsychiatry. The Italian operation markets approximately 200 products across 400 formulations, including the blockbuster antipsychotic Cariprazine (exceeding $1 billion in annual revenue), biosimilars for rheumatology and oncology, generic pharmaceuticals, contraceptive products, fertility treatments, and osteoporosis therapies. Sales are conducted through a direct field force targeting healthcare professionals, hospitals, and pharmacies across Italy.

Product overview

Gedeon Richter Italia Srl is a multinational pharmaceutical company with 125 years of experience, specializing in innovative medicines for Women's Health and Neuropsychiatry. The company operates a unified product portfolio comprising original pharmaceutical products (led by the blockbuster drug Cariprazine), biosimilars developed through its biotechnology division, generic drugs, and a range of women's health products covering contraception, fertility, osteoporosis, and menopause. Beyond pharmaceutical products, the company offers digital educational platforms including the PMA specialist hub, MAG FEM blog, and sustainability-focused initiatives under the GRITness4ALL program. The portfolio spans five therapeutic pillars: Neuropsychiatry (cariprazine and pipeline compounds), Women's Health (gynecology, contraception, fertility), Biotechnology (biosimilars for rheumatology/oncology), Osteoporosis treatments, and Generic drugs. Manufacturing reaches 5 continents with 200 products in 400 formulations.

Differentiator

Problem solved

Functional benefit

Brands

• GRITness4ALL: Corporate social responsibility program focused on female empowerment and culture & education, aligned with UN Sustainable Development Goals.
• My Body Match
• Il Momento Giusto
• ENDOVISION
• I FEEL GRIT
• MAG FEM

Products and services

• Cariprazine Original antipsychotic pharmaceutical product for the treatment of psychiatric and neurodegenerative diseases, including schizophrenia and related conditions. Developed and manufactured by the Gedeon Richter group, it is the company's flagship neuropsychiatry product and is sold to psychiatrists, neurologists, hospitals, and pharmacies through a direct sales network.
• Biosimilars Biosimilar medicines developed to be highly similar to reference biologic drugs with no clinically meaningful differences in quality, safety, or efficacy. Focus areas include rheumatology, osteoporosis, and oncology, sold to specialist physicians, hospitals, and rheumatology/oncology clinics.
• Contraception Products Pharmaceutical contraceptive products under the Women's Health therapeutic area, sold through gynecologists and retail pharmacies in Italy as part of the company's broader gynecology portfolio.
• Osteoporosis Treatments Pharmaceutical treatments for osteoporosis developed through the biotechnology division, targeted at rheumatologists, gynecologists, and hospital prescribers treating post-menopausal women.
• Fertility Products Pharmaceutical fertility treatments and related products sold to fertility specialists, reproductive medicine clinics, and gynecologists as part of the Women's Health portfolio.
• Generic Pharmaceuticals Generic pharmaceutical products across multiple therapeutic areas, complementing the originator drug portfolio to deliver accessible and affordable treatment options to prescribers, pharmacies, and healthcare systems.

Quantifiable outcome

• Cariprazine achieved blockbuster status with $1 billion+ annual revenue
• +4 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

15 partnerships are on record, tiered core, major and minor.

• Edra S.p.A.coreStrategic or Co-development Partner · 1 January 2024ENDOVISION project: multi-stakeholder initiative to accelerate endometriosis diagnosis, standardize care, and reduce territorial inequalities. Project presented at Ministry of Health with multidisciplinary board including clinical experts and patient associations.
• A.L.I.C.E. Odv (Associazione Lotta Italiana per la Consapevolezza sull'Endometriosi)coreGTM or Marketing Partner · 1 January 2022Promotion of Worldwide EndoMarch in Italy, awareness campaign for endometriosis, and funding for a scholarship at IRCCS Ospedale Sacro Cuore Don Calabria di Negrar for specialist training.
• KIKO MilanomajorGTM or Marketing Partner · 1 January 2022Riconoscere l'endometriosi campaign distributing 500,000 information brochures across 330+ KIKO stores nationwide with QR codes linking to an app with specialist center locations.
• Rotary Club Milano NordmajorGTM or Marketing Partner · 1 January 2022Collaboration on endometriosis awareness and prevention campaign with educational materials and screening information.
• Rotarians4healtH (R4H)majorGTM or Marketing Partner · 1 January 2022Development of endometriosis mobile app with information on symptoms, causes, and over 80 specialized centers in Italy.
• IRCCS Ospedale San Raffaele di MilanocoreStrategic or Co-development Partner · 1 January 2021Musica sui tetti streaming event supporting Genome-Wide endometriosis research project. Event with WindRose Orchestra at San Raffaele Hospital roof.
• Ændo (Associazione Italiana Dolore Pelvico ed Endometriosi)majorGTM or Marketing Partner · 1 January 2021Collaboration on endometriosis awareness event Musica sui tetti and ongoing awareness activities.
• Donna ModernaminorGTM or Marketing PartnerVirtual roundtable on endometriosis and desire to become a mother, featuring patient association president and gynecological experts.
• Fondazione SodalitasminorGTM or Marketing PartnerDeploy your Talents initiative promoting gender equality and STEM careers among high school students through school partnerships.
• Fondazione BET SHE CANminorGTM or Marketing PartnerCreation of illustrated book L'età di mezzo for children 8-12 about body changes beyond stereotypes, written by Emanuela Nava and illustrated by Marco Brancana.
• Carthusia PublisherminorGTM or Marketing PartnerPublishing partner for children's book project on body positivity and growth awareness.
• Dott.ssa Chiara Di Pietro (Ginecologa Influencer)coreGTM or Marketing PartnerMy Body Match campaign and Mannaggia al Sesso educational project for sexual education in secondary schools. Cinema events with expert panels addressing contraception and sexual health.
• Helm AGcoreStrategic or Co-development PartnerJoint venture (Richter Helm Biologics) for R&D and production of biologics. Richter holds majority stake. Facility in Hamburg for bacterial and yeast-based protein production.
• Mochida (Japan)majorStrategic or Co-development PartnerStrategic partnership for biosimilar market in Japan to share development costs and risks.
• STADA (Germany)majorStrategic or Co-development PartnerStrategic partnership for biosimilar development in Germany to share risks and investment costs.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Organon & Co. Pure-play women's health pharmaceutical company with leading contraception, fertility, and menopause franchises. Most directly comparable to Gedeon Richter Italia's women's health therapeutic area across Europe.
• Menarini Group: Italy's largest pharmaceutical company with broad women's health, oncology, and specialty franchises. Comparable as a domestic Italian peer operating at greater scale in overlapping therapeutic areas.
• H. Lundbeck A/S: Specialty CNS-focused pharmaceutical company with leading positions in psychiatry and neurodegenerative diseases. Directly comparable to Gedeon Richter's neuropsychiatry franchise, including the cariprazine competing molecule space.
• Chiesi Farmaceutici S.p.A. Italian specialty pharmaceutical company with branded and respiratory/specialty care focus. Comparable as a domestically-rooted Italian pharma with similar specialty positioning and European commercial reach.
• Angelini Pharma: Italian privately-held pharmaceutical group with women's health and CNS franchises. Directly comparable as a domestic Italian peer operating in the same therapeutic areas and channels.
• Recordati S.p.A. Italian specialty pharmaceutical company with branded and rare disease focus across Europe. Comparable as an Italian-based specialty pharma with similar commercial model and therapeutic area overlap.

Broad incumbents

• Bayer AG (Pharmaceuticals): Global incumbent with a major women's health/contraception portfolio (e.g., Yaz, Mirena) overlapping directly with Gedeon Richter Italia's contraception and gynecological franchises, plus scale advantages in Italian market access.
• Sandoz Group AG: Global leader in generics and biosimilars following Novartis spin-off. Comparable as a broad incumbent in biosimilars (rheumatology/oncology) and generic pharmaceuticals, areas where Gedeon Richter's Helm AG JV competes.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with biosimilars portfolio. Comparable as a broad incumbent in the generic drug and biosimilar segments where Gedeon Richter operates.
• Viatris Inc. Global generics and specialty pharmaceutical company with established women's health portfolio. Comparable as a broad incumbent with overlapping women's health and generics footprint in European markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/gedeon-richter-italia-srl
• Instagraminstagram.com/my.body.match

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gedeon Richter Italia Srl